Neurology

MEGIN Oy is a global leader in magnetoencephalography (MEG) technology for functional neuroimaging. The company develops and markets MEG Maps™, an integrated end-to-end solution powered by TRIUX™ neo hardware and MEG review™ software, designed for presurgical evaluation, clinical neurology, neurosurgery, and neuroscience research. MEG technology detects small magnetic fields generated by active brain cells, enabling real-time, non-invasive localization of brain activity to within centimeters or millimeters. MEGIN's systems are non-invasive, silent, radiation-free, and unaffected by skull properties or hemodynamic confounds, offering advantages over traditional fMRI and other functional imaging modalities. The TRIUX™ neo represents an advanced acquisition system with improved signal-to-noise ratios and advanced signal analysis capabilities. MEG Maps™ integrates scan acquisition, database management, and analysis functionality for clinical workflows. The company's solutions are deployed in hospitals and research institutions worldwide, including Mayo Clinic, Amsterdam UMC, Boys Town National Research Hospital, and major research centers. Applications include presurgical mapping for epilepsy and tumor surgery, epilepsy diagnosis and monitoring, brain tumor assessment, traumatic brain injury evaluation, stroke research, neurodegenerative disease investigation (Parkinson's, dementia), PTSD research, and pharmaceutical Phase I/III drug development. MEGIN serves neurology, neurosurgery, oncology, psychiatry, and neuroscience research markets globally.

Fasikl Inc. is a neurotechnology company developing AI-based therapeutic devices for neurological conditions. The company's flagship product, Felix NeuroAI™ Wristband, is a non-invasive wearable device that has received FDA clearance for the treatment of essential tremor. Felix operates through advanced AI technologies that decode and modulate neural signals, delivering all-day symptomatic relief without surgery or medication. The device represents a breakthrough in AI therapeutics, combining cloud-based artificial intelligence with real-time neural signal processing. Fasikl also develops the Fasikl-X™ Nerve-Computer Interface platform for broader neural interfacing applications. The company has invested over 20 years of R&D in neural signal processing and AI-driven treatment modalities. Products are designed for direct patient use and clinical settings, with support for both individual patients and healthcare providers. FDA clearance indicates regulatory approval for the Felix device as a Class II or higher medical device. The company targets essential tremor patients and related neurological indications, positioning itself at the intersection of wearable medical devices, neurotechnology, and artificial intelligence therapeutics.

MeKo Manufacturing e.K. is a contract manufacturer of precision medical components and implants for the interventional and surgical device industry. Founded in 1995, the company pioneered stent manufacturing and is now among the largest contract manufacturers of medical components globally. MeKo specializes in laser cutting, laser welding, and advanced processing of materials including stainless steel (316L, 316LVM), cobalt alloys (L605, Phynox, MP35N), nitinol (NiTi), magnesium alloys (Resoloy®), nickel-free alloys (Vasculoy®), and polymers (PolyMediX®, PLLA, PGA). The company manufactures implants for cardiology, neurology, radiology, ophthalmology, and urology applications, with product lines including metal stents, NiTi stents, hypotubes, retrieval baskets, bone nails, heart valve frames, orthopedic devices, surgical instruments, microcomponents, and drug-delivery balloon catheters. Manufacturing capabilities include CAD/CAM design, precise laser cutting (tolerances below ±5 μm), laser welding, mechanical processing, heat treatment, shape setting, electropolishing, 3D metal printing, polymer coating, marker crimping, and rapid prototyping. The company operates ISO-certified quality management with 100% visual inspection using over 100 specialized high-end microscopes and maintains ISO 8 cleanrooms (Class 100,000). MeKo offers finite element analysis (FEA) simulation services, prototype-to-series production capabilities, and operates 24/7 manufacturing. The company maintains facilities in Germany (Sarstedt, near Hannover), the USA (Bloomington, Minnesota), California, and Costa Rica.

Dongguan Quanding Medical Supplies Co., Ltd. is an OEM/ODM manufacturer headquartered in Shenzhen (established 2008) specializing in medical electrode pads, surgical management consumables, and monitoring system accessories. The company manufactures and distributes across three primary product families: pain management electrodes (TENS pads), patient monitoring electrodes (ECG/EEG), and surgical/electrosurgical accessories (grounding pads, neutral electrodes, patient return pads). Product portfolio includes TENS replacement electrode pads for lower back and muscle pain relief, disposable ECG electrodes in multiple sizes and substrate materials (foam, non-woven fabric), electrosurgical grounding plates and pads for adult and infant use, and medical lead connection wires for high-frequency surgery. The company reports 17+ years of R&D experience, 200+ product categories, and 500+ distribution partners with 99% customer satisfaction. Manufacturing capabilities include design, mold fabrication, sample confirmation, production, strict QC inspection, and after-sale service. Certifications include ISO 9001, ISO 14001, ISO 18001, CE, and API standards. Primary markets are OEM/ODM partners and medical device distributors. No FDA 510(k) clearance mentioned on site.

Accuray Incorporated is a global leader in radiation oncology and radiosurgery systems. The company manufactures advanced treatment platforms designed to deliver precise radiation therapy across a full spectrum of patient needs, with 479+ systems installed in 33+ countries. Accuray's primary product lines include the CyberKnife® S7™, a robotic stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system featuring AI-driven real-time motion synchronization for tumor treatment anywhere in the body, and the Radixact® system, which combines integrated 3D kVCT and megavoltage CT (MVCT) imaging for image-guided intensity-modulated radiation therapy (IG-IMRT) and 3D conformal radiation therapy (3DCRT). Both systems are designed to improve treatment precision, reduce workflow complexity, and enhance patient outcomes. Accuray serves oncology centers, hospitals, and specialized radiotherapy facilities globally. The company emphasizes quality of care, efficiency of workflow, and clinician confidence through continuous innovation. Over 31% of system components are sourced from U.S. suppliers. Accuray supports its installed base through comprehensive training programs, the AEx® peer community platform for user education and experience-sharing, and dedicated service and reimbursement support. The company operates in the high-stakes cancer treatment market, addressing complex cases including prostate, lung, brain, and other tumor types.

PMT Corporation, founded in 1979 and based in Chanhassen, Minnesota, is a manufacturer and distributor of specialty medical products and devices. The company focuses on research and development across neurosurgery, plastic and reconstructive surgery, orthopedic medicine, and gastrointestinal endoscopy. PMT's comprehensive product portfolio includes cortical surface electrodes for epilepsy monitoring, neuronavigation depth electrodes (AccuNav®), cervical traction halo fixation systems, tissue and breast expanders for reconstructive surgery, orthopedic collars and lumbo-sacral orthoses, and micropigmentation and dermabrasion devices. The company also manufactures the ALLURA® vaginal stent and Endomark™ gastric ink markers. Supported by a nationwide US and Canadian sales force and global distributor network, PMT provides 24/7 customer support and delivers sterile surgical supplies and specialized instruments to hospitals, surgical centers, and specialty practitioners.

Surestep, LLC is a pediatric orthotic manufacturer specializing in custom-made braces and orthotic devices for children from infancy through development. The company designs and fabricates ankle-foot orthoses (AFOs), supra-malleolar orthoses (SMOs), cranial remolding helmets, and related lower-extremity support devices. Their product portfolio includes conventional thermoplastic devices and advanced 3D-printed solutions, with recent product innovations including SMO3D (a lightweight, flexible 3D-printed SMO) and Sprout3D (a cranial remolding helmet with demonstrated clinical superiority in head-shape correction). Surestep emphasizes rapid manufacturing turnaround—AFOs in 10–14 business days, SMOs in 4–8 days depending on customization method, and Sprout3D in 7–10 days—enabling quick delivery to pediatric physical therapists, orthopedists, and rehabilitation centers. The company markets its devices for children with balance disorders, gait dysfunction, hypotonia, plagiocephaly, and other developmental orthopedic needs. All devices are custom-engineered for comfort and growth accommodation. Surestep maintains a clinical focus, citing peer-reviewed research (Hanger Institute study) demonstrating superior outcomes with 3D-printed cranial devices. The company serves pediatric rehabilitation, orthopedic, and developmental medicine markets across the US.

Synapse Dental manufactures the Dental Pain Eraser, an FDA-cleared electronic dental anesthesia device that uses patent-pending Advanced Pulsewave Technology to deliver electrical neuromodulation for pain relief and anxiety reduction in dental procedures. The device eliminates the need for traditional needle anesthesia in many applications, including general dentistry, orthodontics, pediatric dentistry, oral surgery, and endodontic therapy. The Dental Pain Eraser delivers topical pain relief in seconds before patients enter the operatory chair and can be used throughout treatment. The company reports clinical validation through peer-reviewed publications in the Journal of Clinical Orthodontics, Lasers in Medical Science, International Journal of Paediatric Dentistry, and others. The device has received multiple industry awards including three consecutive American Association of Orthodontists (AAO) New Products Showcase Awards (2025, 2024) and the 2023 Ortho Innovator Award. Recent product innovations include the Delta Rail tip for enhanced anesthesia delivery in invasive procedures. The company markets the device to dental practices as a practice differentiator that improves patient experience, increases treatment acceptance rates, and enhances operational efficiency. FDA clearance and clinical evidence support use across multiple dental disciplines for pain management and anxiety reduction.

Cretex Medical

Cretex Medical is a division of the Cretex Companies, specializing in end-to-end contract manufacturing for the medical device industry. With over 100 years of history, the company provides critical components, assemblies, packaging, and sterilization services. It supports medical device OEMs from development through to finished device production, emphasizing quality, operational excellence, and innovation. The company operates multiple specialized businesses, including CDT, Quality Tech Services (QTS), rms, and Meier, each offering unique capabilities. CDT focuses on high-precision components and assemblies, while QTS provides end-of-line services such as assembly, packaging, and sterilization validations. rms specializes in tight-tolerance implantable devices and custom instrumentation, and Meier produces micro-sized components for various medical applications. Cretex Medical serves OEMs in sectors like cardiovascular, neuromodulation, orthopedics, and defense, prioritizing long-term partnerships and reliability in manufacturing.

ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. is a global medical technology company focused on navigation and delivery solutions for the brain and spine. Founded in 1994, it has become a leader in minimally invasive neurosurgery, providing the ClearPoint® System, which enables precise instrument navigation and therapeutic delivery for various neurological conditions. The company emphasizes real-time imaging and patient comfort, aiming to improve the quality of life for patients with complex neurological disorders. Headquartered in Solana Beach, California, ClearPoint operates a Global Training & Innovation Center and collaborates with over 90 neurosurgery centers worldwide. It supports more than 7,000 procedures and partners with over 60 organizations in biologics and drug delivery. ClearPoint offers a comprehensive platform that includes clinical solutions, biologics and drug delivery services, research collaboration opportunities, and training for healthcare professionals. Its integrated approach combines hardware, software, and real-time MRI-guided workflows to enhance the effectiveness of neurosurgical interventions.

UprightVR Inc. develops an FDA-registered, immersive virtual reality system for balance assessment, rehabilitation, and fall prevention. The platform combines VR technology with neuroscience-based diagnostics to measure sensory-motor integration and vestibular function in 8 minutes, generating detailed clinical and patient reports. Primary markets include physical therapy clinics, senior living communities, rehabilitation hospitals, and medical practices. The system includes RecoVR™ therapeutic rehabilitation modules—gamified exercises designed for patients with concussions, strokes, balance disorders, Parkinson's disease, cerebellar ataxia, hearing and balance impairments, and post-injury recovery. Assessment tools include SafetyNet™ for detecting hidden balance deficits and VOR (vestibular ocular reflex) retraining games. The company emphasizes portable, affordable deployment requiring minimal space and setup. Revenue model targets higher insurance reimbursement rates for advanced balance assessment and therapy. Developed by Geoffrey Wright, Ph.D., Professor of Neuromotor Sciences at Temple University, with two decades of clinical research validation across diverse patient populations. Offers comprehensive customer support including onboarding, remote and on-site training, clinical consultations, and data analytics. Continuous software updates add new assessments and rehabilitation modules.

InterX Technologies manufactures FDA-cleared, non-invasive neuromodulation devices for the treatment of acute, post-surgical, and chronic neuropathic pain. The company's primary product line includes the InterX® 5002 (professional) and InterX® 1000 (personal) devices, which deliver interactive neurostimulation directly to the skin without conductive gel. Both devices employ patented flex array impedance-seeking electrode pads and are compatible with multiple electrode accessories, including the newly launched XPad®—a flexible, adhesive, cut-to-fit conductive pad for dynamic muscle groups and high-movement zones. InterX devices are used across clinical, sports medicine, military, and home-care settings. The company serves physical therapists, chiropractors, athletic trainers, healthcare professionals, and individual patients. Markets include professional sports (NFL, NBA, MLB, NHL), U.S. military and Veterans Affairs, academic medical centers (Duke Health, Texas Health), and specialized therapy clinics. All devices and accessories are backed by broad patents and clinical evidence. InterX operates training centers and licensing programs for healthcare professionals. The company ships within the United States only.

C2C Development, LLC is an FDA-registered, ISO 13485:2016-certified contract manufacturer and product development firm specializing in medical device design, prototyping, and low-volume manufacturing. The company operates a certified ISO 7 (Class 10,000) cleanroom environment and serves medical device innovators across laparoscopic, endoscopic, orthopedic, intravascular, neurological, stereotactic, and drug delivery applications. Services include comprehensive design control and prototyping using 3D modeling, 3D printing, conventional machining, and CNC machining; component sourcing and supplier qualification under ISO 13485 quality systems; assembly and packaging operations including kitting, cleaning, and inspection; verification and validation testing including packaging seal integrity, shelf-life, and mechanical/functional testing; sterilization management and laboratory testing coordination; and regulatory strategy consultation and submission support. The firm specializes in manual and semi-automated assembly for products that larger OEMs may not accommodate, enabling manufacturers to scale from pilot production to commercial release under either C2C's or the client's quality system. Clients include Medtronic, FHC, Monteris, and other established medical device manufacturers.

PASCALL SYSTEMS INC. is a Boston-based medical device company specializing in precision EEG-guided anesthesia management. The company develops a wearable brain monitoring platform that uses advanced signal processing and electroencephalography (EEG) to optimize intraoperative anesthetic administration. The platform aims to reduce unnecessary anesthetic exposure, thereby improving postoperative outcomes and preventing complications such as postoperative delirium (POD) and opioid dependence. The technology integrates real-time physiological data analysis, control engineering, and AI-driven decision support to empower anesthesiologists with personalized, data-driven anesthesia dosing. PASCALL's solution is designed to comply with FDA regulations and operates under rigorous quality management systems. The company focuses on signal extraction, artifact removal, and state-space modeling of brain activity to deliver clinically actionable insights during surgery.

Medeia Inc is a manufacturer and distributor of neurodiagnostic and cardiovascular physiological monitoring systems. Founded in 1992, the company specializes in state-of-the-art biometric hardware and software for autonomic nervous system assessment, vascular analysis, EEG/EEG-derived diagnostics, and sleep studies. Medeia's product portfolio serves neurologists, cardiologists, primary care physicians, and research institutions with comprehensive tools for objective physiological measurement, including autonomic function testing (ANS), pulse wave velocity analysis, peripheral neuropathy assessment, and neuroencephalography. The VitalScan product line addresses autonomic and vascular diagnostics; BrainView systems provide EEG and cognitive assessment; NeuroTrace offers ambulatory wireless EEG; SleepStudy delivers polysomnography; and CardioView supplies mobile cardiac telemetry. Products are designed for clinical workflow efficiency and are distributed internationally to healthcare providers and research facilities.

WR Medical Electronics Co. is a manufacturer of autonomic and peripheral neuropathy diagnostic testing systems and software. The company specializes in integrated solutions for quantitative assessment of autonomic dysfunction, syncope, POTS (postural orthostatic tachycardia syndrome), neuropathy, and hyperalgesia. Core product offerings include the WR Head-Up Tilt Table for syncope and POTS evaluation, WR HRV Acquire for heart rate variability and beat-to-beat blood pressure monitoring, WR Q-Sweat QSART (quantitative sudomotor axon reflex test) device for sudomotor assessment, CASE IV Peripheral Testing System for quantitative sensory testing (QST) including vibration, touch, heat, and cooling sensation, and WR Testworks Software for integrated data acquisition and analysis. The company's validated testing protocols combine cardiovagal, sudomotor, and adrenergic assessments into comprehensive clinical reports. WR Medical serves private practices, clinics, hospitals, academic research institutions, universities, and pharmaceutical/clinical trial sponsors. The company offers personalized installation, training, and ongoing technical support. Over 30 years of experience developing solutions in collaboration with autonomic and peripheral neurology pioneers. Customers include facilities at major international medical conferences (AANEM, MEDICA). Products are used for clinical diagnosis, research endpoints, and normative data establishment across multiple geographic populations.

NeurAxis, Inc. is a medical device company specializing in neuromodulation therapies for chronic and debilitating conditions, particularly disorders of the gut-brain interaction (DGBI). The company manufactures IB-Stim, an FDA-cleared, wearable percutaneous electrical nerve field stimulation (PENFS) device worn behind the ear for treating functional abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia (FD), including FD-related nausea symptoms. IB-Stim is indicated for patients 8 years and older and represents a drug-free, non-surgical alternative. The company has secured multiple payer coverage policies, Veterans Affairs Federal Supply Schedule contracts, and established permanent reimbursement pathways through AMA Category I CPT codes. NeurAxis is committed to improving patient outcomes and reducing suffering through innovation in neuromodulation technology.

huMannity Medtec

huMannity Medtec is a non-profit medical research and development organization based in Santa Clarita, California. Founded in 1985 by Alfred E. Mann, the organization focuses on creating innovative medical technologies to meet the needs of patients with limited treatment options. Rebranded in September 2023, huMannity Medtec is dedicated to addressing challenging healthcare issues through its research and development efforts. The organization specializes in implantable devices, drug delivery systems, and neuromodulation technologies. Its notable products include cochlear implants, insulin pumps, and retinal prosthetics. Over the years, huMannity Medtec has successfully launched several spinoff companies that have collectively achieved around $8 billion in market value. The organization also offers comprehensive development services, including concept development, prototyping, clinical trials, and commercialization partnerships, ensuring a robust pathway from innovation to market readiness.

Specto Medical AG is a Swiss medtech software company founded in 2022 as a spin-off from the University of Basel. The company specializes in real-time 3D visualization software that converts CT and MRI scans into immersive virtual reality (VR) and augmented reality (AR) experiences. The platform transforms traditional 2D medical imaging into interactive 3D anatomical models, enabling surgeons and clinicians to gain instant spatial understanding of complex anatomical structures before, during, and after surgical procedures. The software supports clinical decision-making, patient education, and surgical planning with FDA clearance and full CE certification. Primary applications include cranial neurosurgery, brain aneurysm and tumor procedures, and complex anatomical case planning. The company offers seamless DICOM integration and volume rendering technology with lightning-fast processing times and anatomically accurate visualizations.

Neurofeedback Supply and Equipment of Texas is the exclusive importer and distributor of the NeuronSpectrum line of EEG amplifiers in Texas. The company supplies clinical-grade EEG amplifiers (19–21 channel systems) for quantitative EEG (qEEG) analysis, clinical EEG recording, and neurofeedback training applications. Beyond equipment sales, the company provides comprehensive training and technical support to neurofeedback clinicians—both new and experienced—and assists mental health professionals in establishing brain-based clinical practices. They offer scalable solutions for small to large group practices, including staff selection, training, and practice development services.

eCential Robotics is a surgical robotics company specializing in an open, unified platform integrating 2D/3D imaging, real-time navigation, and robotic systems for bone surgery. Founded in 2009 and headquartered in Grenoble, France, with US operations in Franklin, Tennessee, the company serves orthopedic and neurosurgery markets with over 3,500 completed procedures. The platform is implant-agnostic, supporting third-party surgical app development and compatible with implants from multiple manufacturers, allowing surgeons to select the optimal technique and device for each patient. Key features include integrated imaging and navigation within a single interface, support for minimally invasive approaches, and multi-specialty surgical applications. With over 100 patents and approximately 105 employees, eCential Robotics focuses on digitalizing traditional surgical techniques to enhance patient safety, surgeon precision, and operational efficiency in the OR.

Professional Surgical Instruments Co., Inc. is a comprehensive manufacturer and distributor of surgical instruments serving the global medical, dental, and veterinary markets. Based in East Brunswick, New Jersey, the company specializes in precision-engineered stainless steel surgical instruments across multiple specialties. Their extensive product portfolio includes forceps, needle holders, scissors, retractors, clamps, elevators, rongeurs, and specialized instruments for cardiothoracic, orthopedic, neurosurgical, laparoscopic, microsurgical, ophthalmic, ENT, OB/GYN, dermatology, plastic surgery, and pediatric procedures. The company also manufactures dental surgical instruments, endodontic tools, orthodontic instruments, periodontal instruments, and restorative dental tools. Products are available in both individual instruments and pre-assembled surgical sets. Professional Surgical Instruments maintains a B2B focus, offering medical device manufacturing expertise and a detailed surgical instrument catalog to hospitals, surgical centers, dental practices, and veterinary clinics worldwide.

ISO 13485-certified manufacturer and distributor of electrodiagnostic neuro supplies since 1975. The Electrode Store specializes in needle electrodes (monopolar, concentric, hypodermic), surface electrodes, electrode gels, pastes, and accessories for EMG, EEG, NCS, IONM, and ERG applications. Products support diagnosis of neurological and neuromuscular disorders including carpal tunnel syndrome and epilepsy. The company offers both human and veterinary electrodiagnostic solutions, with proprietary surgical stainless steel needles featuring conical sharpening and proprietary insulation coating. FDA-registered with ISO 13485, MDSAP, and CE Mark certifications. Manufacturer of the DPNCheck nerve conduction device for peripheral neuropathy diagnosis and monitoring.

Persyst Development LLC is the worldwide leader in EEG (electroencephalography) software for clinical neurodiagnostics. The company develops and markets Persyst 15 (P15), a comprehensive Computer Assisted Review of EEG (C.A.R.E) platform that provides advanced tools for EEG data review, analysis, and monitoring. Core capabilities include automated seizure detection, spike detection, artifact reduction, and EEG trending analytics designed to support both high-volume institutions and community clinics. Persyst's seizure detection algorithm has been validated in peer-reviewed literature (Journal of Clinical Neurophysiology) as statistically noninferior to skilled human reviewers. The company also offers Persyst Mobile, the first FDA-cleared EEG monitoring and review application for mobile devices, enabling remote access to EEG data. Persyst is integrated with and sold/supported by every major EEG hardware manufacturer, including Micromed, Natus, Nihon Kohden, Cadwell, and Compumedics. The software is recognized as the standard of care, with adoption at 211 of 233 US News-ranked neurology and neurosurgery centers. The company maintains a strong commitment to clinical research and scientific validation, publishing findings in peer-reviewed journals and hosting educational events such as Persyst Grand Rounds.

Control Bionics is an Australian medical device company specializing in augmentative and alternative communication (AAC) technologies and assistive devices for individuals with speech impairment, paralysis, and movement limitations. The company develops wearable biosensor systems and speech-generating devices that enable users with degenerative neurological conditions, spinal cord injuries, cerebral palsy, and similar disorders to communicate and control external devices through bioelectric signals or spatial eye-gaze control. Core products include the NeuroNode Trilogy and Duo systems (speech-generating devices with wireless wearable sensors), EyeGaze Duo (eye-tracking communication system), UnoTouch (portable control device), and NeuroStrip (miniaturized EMG sensor for physiological monitoring). The company also develops solutions for sports performance optimization and physical rehabilitation applications. Control Bionics serves clinical, home care, and athletic markets across Australia, North America, and internationally.

Precision Neuroscience

Precision Neuroscience is a neurotechnology company founded in 2021 that specializes in developing minimally invasive brain-computer interfaces (BCIs) aimed at treating neurological disorders. The company focuses on high-resolution, non-penetrating cortical surface arrays that record brain signals without damaging tissue. Its flagship product, the Layer 7 Cortical Interface, is a thin-film microelectrode array designed to capture detailed brain activity, enabling thought-controlled actions. Co-founded by neurosurgeon Ben Rapoport and business builder Michael Mager, Precision Neuroscience has expanded its team and established its own manufacturing facility. The company has conducted human clinical trials and received FDA clearance for its core device, with commercial products expected soon. Precision's mission is to create safe, removable BCIs that enhance communication and independence for individuals with severe conditions such as paralysis and speech deficits. The company collaborates with notable institutions like the Rockefeller Neuroscience Institute and Mount Sinai Health System to advance its clinical development efforts.

Nautilus Surgical is a distributor and solutions partner specializing in high-quality microsurgical equipment and operating room systems for hospitals and manufacturers. The company represents leading international medical device manufacturers including Carl Zeiss Meditec, UFSK-OSYS, Otopront, Mizuho, Steribite, Surgix, Cuda Surgical, Barrier Technologies, Kogent Surgical, Hubly Surgical, Neurovision Medical Products, MediCapture, and TTI Medical. Product portfolio encompasses advanced surgical microscopy systems (ZEISS KINEVO 900 S with digital visualization and cobotic assistance), surgical tables optimized for ophthalmology and neurosurgery, ENT examination chairs (Otopront Sit Max One, BASIC PLUS Flat Top), spinal and neurosurgical instruments, single-use surgical sets, cranial access kits, intraoperative neuromonitoring devices, surgical light sources, fiberoptic cables, radiation protection solutions, and medical-grade video recording and documentation systems. Nautilus Surgical also offers ZEISS Certified factory-reconditioned instruments. The company serves multiple surgical specialties including ophthalmology, neurosurgery, spine surgery, ENT, and microsurgery. Known for knowledgeable sales consultants and reliable technical support to support surgical workflows across hospital operating rooms and ambulatory surgical centers.

LifeStance Health

LifeStance Health is a prominent outpatient behavioral health provider in the U.S., founded in 2017 and headquartered in Scottsdale, Arizona. The company operates over 550 centers across 33 states and offers nationwide telehealth services. LifeStance is publicly traded on NASDAQ under the ticker LFST, having completed its IPO in 2021. The company provides a range of mental health services, including therapy and counseling for individuals, couples, and families, as well as psychiatry and medication management. LifeStance also offers psychological testing and specialized treatments like Transcranial Magnetic Stimulation (TMS) and ketamine therapies. With a focus on evidence-based care, LifeStance emphasizes personalized treatment plans and continuity of care, accepting over 160 commercial insurance plans and some Medicaid options. The company employs around 7,500 licensed mental health professionals and has adapted its services to include a significant telehealth component, making mental health care more accessible to patients.

Spark Biomedical Inc is a Dallas-based medical device manufacturer specializing in wearable neurostimulation solutions for complex care scenarios. The company's flagship FDA-cleared product, Sparrow Ascent, utilizes Transcutaneous Auricular Neurostimulation (tAN®) technology to deliver non-invasive, targeted bioelectronic medicine. Primary clinical applications include opioid withdrawal relief and medication reduction, with the platform expanding into neurological health, pediatrics, hemostasis, and women's health. The company conducts clinical trials and collaborates with leading healthcare organizations including the Veterans Administration, Hazelden Betty Ford Foundation, and the National Institutes of Health to advance drug-free treatment options and improve patient outcomes.

RTsafe is a medical technology company specializing in quality assurance solutions for radiation oncology and stereotactic radiosurgery. The company develops patient-specific anatomical phantoms using advanced 3D printing technology based on patient CT scans to enable precise dosimetry verification and pretreatment quality assurance. RTsafe's flagship product, the FDA-cleared PseudoPatient®, replicates individual patient anatomy for accurate dose measurement and treatment planning validation. The company also offers the Prime Phantom for linear accelerator quality assurance, the SBRT Phantom for abdominal stereotactic body radiotherapy planning, customized phantom services, and remote dosimetry audit services. RTsafe's solutions support radiation oncologists, medical physicists, and treatment centers globally in achieving minimum-achievable-risk radiotherapy through rigorous end-to-end treatment chain validation.

BEE Medic is a global supplier of high-precision EEG-based medical equipment and software for neurofeedback, biofeedback, diagnostics, and EEG research. The company serves licensed mental health professionals, clinicians, and research institutions with FDA-cleared, modular systems developed in collaboration with clinical partners and research institutions. BEE Medic's product portfolio includes the NeuroAmp II amplifier family for EEG recordings, the Sync Box for ERP synchronization, and the Combi Sensor for biofeedback measurements. Software platforms such as Cygnet and BEE Lab support various neurofeedback training protocols and real-time brainwave feedback applications. The company operates as part of the BEE Group AG network with offices in the USA, Germany, Switzerland, and the UK, and provides comprehensive support including hands-on training courses, technical assistance, and clinical education to help practitioners implement neurofeedback therapies for ADHD, chronic pain, autism, PTSD, and other conditions requiring brain self-regulation.

Vielight Inc manufactures photobiomodulation (PBM) devices for consumer and clinical use, specializing in transcranial and intranasal light therapy systems targeting brain health and systemic wellness. The company's core technology uses safe, non-ionizing red and near-infrared light energy to stimulate mitochondrial ATP production, with applications in cognitive enhancement, neurological conditions, and immune support. Product lines include the Neuro series (Pro 2, Duo, Gamma, Alpha variants) for brain photobiomodulation targeting Alzheimer's disease, traumatic brain injury, Parkinson's disease, mild cognitive impairment, autism, and PTSD; the Vagus device for non-invasive vagal nerve stimulation; the MIP for systemic wellness and immunity; and the X-Plus for thymus stimulation. Vielight has published 30+ peer-reviewed studies in collaboration with leading institutions including UCSF, Harvard, University of Toronto, Boston University, and University of Utah, with 20+ ongoing clinical trials and 800+ research participants. The company holds Health Canada medical device approval and conducts FDA-regulated clinical studies. Devices are marketed directly to consumers, practitioners, athletes, and military/veteran populations. Manufacturing and logistics are based in Hayward, California; administration in Toronto, Ontario; and a USA sales office in Shepherdstown, West Virginia. Over 100,000 devices sold globally with a 4.8/5 customer rating.

Anuncia Medical is a neurotherapeutic medical device company based in Scottsdale, Arizona, specializing in cerebrospinal fluid (CSF) management and neurocritical care solutions. The company develops noninvasive, clinically validated breakthrough devices designed to monitor, treat, and prevent shunt occlusions in patients with hydrocephalus. The ReFlow™ System Mini (ReFlow™ Mini Flusher) is their primary offering—an implantable device that allows patients to perform noninvasive CSF flushes by pressing the flusher located under the scalp, potentially restoring or maintaining shunt patency and reducing the need for repeat revision brain surgeries. The device received FDA Breakthrough Device Designation, indicating significant clinical potential. Anuncia addresses the substantial unmet need in hydrocephalus management, particularly affecting pediatric and geriatric populations. The company's team comprises medical device veterans collaborating with leading institutions and clinicians. Their technology targets both in-clinic and at-home management scenarios, reducing patient morbidity and healthcare costs associated with shunt revision procedures. The ReFlow™ Mini Flusher can be used with the ReFlow™ Ventricular Catheter, which features a relief membrane backup option providing alternate CSF flow pathways. Regulatory credentials include FDA Breakthrough Device Designation. The company actively engages with patient communities and professional associations to support hydrocephalus awareness and clinical education.

MEDIVIS develops FDA-cleared augmented reality (AR) and surgical navigation software for intraoperative guidance and preoperative planning. The company's flagship product, SurgicalAR, transforms 2D cross-sectional imaging (CT, MRI) into high-fidelity 3D visualizations with real-time surgical navigation and spatial computing capabilities. Primary offerings include: Spine Navigation (FDA-cleared for open and minimally invasive spine procedures), Cranial Navigation (FDA-cleared for EVDs, subdural evacuations, and craniotomies), and Prostate Navigation (research-stage for biopsies and ablations). SurgicalAR features on-premise IT infrastructure with certified gold-standard security, infrared instrument tracking by specialty, photorealistic 3D renderings, model segmentation, livestream imaging to virtual monitors, spatial hand and voice interactions, and an integrated AI agent (Maia, coming soon). Hardware platforms include Medivis PRO (27" touch monitor, 4K graphics, NVIDIA GPU for operating rooms), Medivis CORE (17" portable workstation for ICUs and clinics), and Medivis VIEWER (spatial computing visualization for planning). The company has deployed across 40+ hospitals and medical schools, with 2,000+ surgeries performed using SurgicalAR. Regulatory clearances include FDA 510(k) clearance for spine and cranial modules, CE marking, and Korea FDA clearance. The technology integrates with existing surgical workflows and imaging systems, supporting neurosurgery, orthopedic, and urological specialties. Recognized by TIME Magazine (Best Inventions 2023), Fast Company (Most Innovative 2024), and as Edison Award finalist (2024).

DEYMED Diagnostic is a Czech-headquartered manufacturer of advanced neurophysiology and psychiatry diagnostic and treatment systems, operating since 1997. The company designs and manufactures EEG (electroencephalography), EMG (electromyography), PSG (polysomnography), TMS (transcranial magnetic stimulation), and biofeedback systems for clinical and research applications. Products are distributed across 60+ countries with over 12,000 units installed globally. All devices are engineered to ISO 13485 and FDA 21 CFR Part 820 quality management standards, comply with EN 60601 safety requirements, and carry CE marking. The company operates a multi-functional product portfolio: TruScan EEG for portable, clinical, and long-term monitoring; TruTrace EMG for nerve conduction studies, electromyography, and autonomic nervous system assessment (battery-powered, configurable as cart or portable); SomniPro PSG for sleep studies; DuoMAG rTMS/TMS systems (monophasic and biphasic variants) for clinical and research brain stimulation; and BrainFeedback/neurofeedback systems for neurotraining. The company emphasizes close collaboration with clinical specialists during development, strict quality testing, and comprehensive technical support including remote assistance tools. Service and support are available Monday–Friday, 8:00–17:00 CET, with both quick and unattended remote support applications provided. Systems are designed to run on Windows 7 through Windows 10 on standard desktop or laptop hardware.

BioRESEARCH, Inc. is a dental and medical device manufacturer specializing in precision biometric equipment for functional dentistry, temporomandibular joint (TMJ) assessment, and neuromuscular evaluation. The company develops advanced diagnostic and therapeutic technologies that measure objective biometric data to support clinical decision-making in dental, orthopedic, and otolaryngologic applications. Key product lines include the BioEMG III, an advanced surface electromyography system for muscle activity recording and neuromuscular assessment; BioJVA (Joint Vibration Analysis), a non-invasive TMJ screening tool measuring vibration patterns during jaw movement; and the JT-3D Jaw Tracker, which provides high-precision 3D mandibular kinesiography with incisor-point path analysis. The company also distributes complementary diagnostic tools such as the T-Scan NOVUS for occlusal force analysis and the GMI NARIS for acoustic rhinometry and rhinomanometry in nasal airway assessment. Therapeutic offerings include the QuadraTENS (dual-channel ULF-TENS for muscle relaxation), M-Scan (portable surface electromyography), MLS Laser Therapy systems, and DEKA CO₂ lasers for soft-tissue procedures. All devices integrate with BioRESEARCH's BioPAK software platform for data analysis, interpretation, and patient management. The company serves general dentists, prosthodontists, orthodontists, sleep medicine practitioners, and otolaryngologists. Products are designed for clinical integration with real-time biofeedback, objective data capture for diagnosis and treatment monitoring, and enhanced patient communication and case acceptance. BioRESEARCH provides comprehensive continuing education courses covering Total BioPAK Interpretation (TBI), advanced TMD applications, and practice integration. Customer support includes an AI-powered chatbot (BioBOT) for device operation and software questions.

Ceribell develops point-of-care EEG systems for rapid seizure detection and monitoring in critical care settings. The company's flagship product, a portable EEG platform integrated with the CLARITY® AI algorithm, enables bedside detection of seizure activity, including non-convulsive seizures, in ICUs, emergency departments, and neurology units. CLARITY® is FDA-cleared for pediatric and neonatal patients, representing the first and only FDA-cleared seizure detection algorithm for newborns preterm and up. The system delivers 95% sensitivity and 97% specificity for status epilepticus detection with 99.9% negative predictive value. Ceribell's secure cloud portal features FedRAMP High cybersecurity authorization for telemedicine consultation and remote EEG interpretation. Clinical evidence demonstrates the platform is associated with 4.1-day shorter median ICU stays and improved neurological outcomes compared to conventional EEG workflows. The company supports hospitals with ongoing in-person and virtual training. Target markets include intensive care units, emergency departments, and neurology departments in acute-care hospitals. Ceribell holds multiple FDA clearances (510(k)), CE mark certification, and has published 45+ peer-reviewed publications validating diagnostic accuracy and clinical utility in critical care populations.

Beacon Biosignals is an AI-driven neurotechnology company specializing in clinical-grade sleep EEG capture and biomarker analysis for drug development and clinical research. The company develops FDA-cleared headband devices (Dreem 3S) that collect high-fidelity sleep electroencephalography data in home and clinical settings, paired with proprietary AI algorithms trained on 200,000+ hours of EEG recordings. Beacon's end-to-end platform supports translational research, clinical trial optimization, and real-world clinical practice across psychiatric disorders (major depressive disorder, schizophrenia, bipolar disorder), neurological conditions, and primary and secondary sleep disorders. The company provides quantitative sleep endpoints and pharmacodynamic biomarkers to identify dose-dependent drug effects, characterize and stratify patient populations, support label expansion claims, and track disease progression. Services include full-service clinical trial support with Clinical Study Operations and Scientific Services teams managing device setup, software integration, data quality assurance, and regulatory reporting. Beacon's technology enables objective measurement of sleep architecture and brain function, reducing participant and site burden compared to traditional methods. The platform integrates secure data upload, low-latency event monitoring for compliance and treatment response assessment, and analytics for cohort identification. Beacon is backed by significant venture funding (Series B upsized to $97 million+ as of April 2026) and serves pharmaceutical development, clinical research organizations, and academic institutions. Products are restricted to clinical trial, diagnostic, and academic research use and are not available for individual consumer purchase.

LVIS Corporation is a San Francisco Bay Area–based medical technology company specializing in neural information analysis and EEG diagnostics software. The company develops patented brain-imaging visualization and analysis technologies that decode brain network activity to support neurological disease diagnosis and clinical workflows. LVIS's flagship product is NeuroMatch®, a cloud-based SaaS platform that automates and enhances EEG examination, source localization, and 3D/4D brain visualization. NeuroMatch has received FDA 510(k) clearance (K250239) in the United States and MFDS regulatory clearance in South Korea. The platform addresses critical gaps in neurological healthcare capacity: the shortage of neurologists (1 per 23,259 people), sub-optimal clinical workflows, and surging demand for neurological diagnosis. LVIS is backed by prestigious academic partnerships, including Stanford Byers Center for Biodesign Faculty Fellowship, Stanford StartX incubator, and NVIDIA Inception Program support. The company has received research grants from the Stanford Spectrum Center, LivaNova, and the Epilepsy Foundation. Leadership includes neuroscience and engineering experts; the company was founded by Jin Hyung Lee, PhD. NeuroMatch was named a 2026 Edison Awards finalist. The company operates with headquarters in Palo Alto, California, and additional offices in Gangnam and Daegu, South Korea, serving both US and international markets.

Limber Health is a digital health platform serving physical and occupational therapy organizations. The company provides a comprehensive, cloud-based solution designed to extend in-person rehabilitation care into the home environment through Remote Therapeutic Monitoring (RTM), digital home exercise programs (HEP), patient-reported outcomes (PROs) collection, and value-based care support. The platform features a library of over 7,000 professionally produced exercise videos spanning multiple specialties: musculoskeletal and orthopedic therapy, vestibular rehabilitation, hand therapy, pediatrics, neurology, pelvic health, craniomandibular/TMJ, and orofacial therapy. Limber offers 100+ pre-built clinical protocols for non-surgical conditions, surgical procedures, and orthobiologic interventions. The platform includes integrated MIPS reporting and CMS-approved Qualified Clinical Data Registry (QCDR) functionality to support value-based care and compliance. Key features include real-time data analytics, patient adherence tracking, automated outcomes collection, care navigation with licensed therapy professionals, and seamless EMR integration. Clinically validated through research at Mayo Clinic, the platform is designed to improve patient engagement, outcomes, and operational efficiency while reducing administrative burden for therapy practices. Trusted by leading rehabilitation networks and independent practices across the United States.

NeuFit (operating as Neurological Fitness Equipment and Education LLC) manufactures and distributes the Neubie, an FDA-cleared direct current (DC) electrical stimulation device designed for tissue healing, neuromuscular re-education, and neurological rehabilitation. The Neubie is used across orthopedic recovery, neurological conditions (stroke, spinal cord injury, traumatic brain injury), athletic performance enhancement, and pain management. The company provides a comprehensive methodology called the NeuFit Method, which combines device stimulation with targeted movements and manual techniques to identify neurological limitations, reset dysfunctional patterns through neuroplasticity, and facilitate functional breakthroughs. The platform serves physical therapists, occupational therapists, chiropractors, physicians, athletic trainers, and sports teams. NeuFit reports 400+ clinics, 4,000+ certified practitioners, 75+ professional sports teams, and 15+ universities using the Neubie. Clinical outcomes reported include 90% of users experiencing tangible improvements in the first session, with reductions in pain, increased mobility, improved range of motion, and accelerated recovery timelines. The device is FDA-cleared (510(k)) and subject to US regulatory requirements limiting commercial use to licensed practitioners or under licensed practitioner supervision. The company emphasizes education through practitioner certification programs and provides business support materials for clinical practices incorporating the technology.

GrayMatters Health develops Prism, an interventional psychiatry software platform that leverages fMRI-informed digital biomarkers and EEG neurofeedback to deliver personalized psychiatric care. The company's core technology uses real-time brain activity monitoring via EEG sensors to help patients self-regulate neural patterns associated with mental health conditions. Prism offers clinically validated protocols for PTSD (utilizing amygdala-based biomarkers) and Major Depressive Disorder (targeting ventral striatum reward-system activity). The platform integrates into clinical workflows, allowing technicians to administer sessions under clinician supervision, optimizing operational efficiency. GrayMatters emphasizes evidence-based design with published clinical studies demonstrating efficacy in symptom reduction and improved patient outcomes. The company provides comprehensive support including onsite installation, staff training, and ongoing technical assistance. Prism represents a bridge between neuroscience research and accessible psychiatric practice, enabling clinicians to augment standard-of-care therapies with objective, brain-derived biomarker data. The technology is designed for clinic deployment with minimal storage footprint and seamless integration into existing treatment protocols.

Boston Scientific Corporation is a global medical device manufacturer serving multiple clinical specialties including cardiology, urology, gastroenterology, interventional radiology, electrophysiology, neurology, pain management, vascular surgery, and structural heart disease. The company manufactures and distributes a broad portfolio of minimally invasive medical devices, including cardiac rhythm management systems, interventional cardiology devices, electrophysiology catheters and mapping systems, spinal cord stimulation systems for pain management, urological devices, endoscopy and visualization systems, defibrillators, and interventional oncology equipment. Boston Scientific operates a healthcare professional portal providing online training through EDUCARE, e-commerce ordering, reimbursement resources, and comprehensive customer support with specialty-specific representative contact networks. The organization serves hospitals, ambulatory surgery centers, and healthcare professionals across the United States through direct sales and support teams organized by medical specialty. Products undergo rigorous regulatory compliance (FDA 510(k), international certifications) and the company emphasizes quality assurance and product safety as core organizational values. Customer care is available via a dedicated U.S. customer service line, with extended business hours Monday–Friday.

MaxMoreSpine designs and distributes minimally invasive endoscopic spine surgery systems for the treatment of degenerative spinal disorders, lumbar disc herniation, and facet joint pathology. The company manufactures a portfolio of transforaminal, interlaminar, intradiscal, and cervical endoscopic systems that enable surgeons to perform spinal procedures using local anesthesia with reduced instrumentation, lower disposable costs, and improved patient safety compared to traditional open surgery. Primary product lines include the PTED Endoscopic System (percutaneous transforaminal endoscopic decompression), PSLD Endoscopic System (posterior interlaminar lumbar decompression), MaxFusion by Dr. Morgenstern (endoscopic transforaminal lumbar interbody fusion), Biportal Endoscopic System, J@blation System (facet joint ablation), and cervical mini systems. MaxMoreSpine serves orthopedic and neurosurgeons, pain management physicians, and hospitals globally. The company actively supports continued medical education through hands-on workshops, cadaveric training programs, and participation in international conferences. Products feature 4K visualization capabilities and neurological safety monitoring. Based in San Diego, California, MaxMoreSpine maintains European operations and distributes systems internationally.

Rezzimax, LLC manufactures the Rezzimax Pain Tuner, a non-invasive, handheld neurological device designed to stimulate the vagus nerve and central nervous system through variable vibration frequencies. The device is intended to improve nerve function, enhance blood flow to affected areas, and support natural pain relief and symptom management. Clinical applications include treatment of TMJ/TMD, sinus congestion, neck pain, chronic pain, neuropathic conditions (post-herpetic neuralgia), Parkinson's disease symptom management, and recovery of sensory function (anosmia). The company offers two primary product lines: the Rezzimax Tuner Pro II, a full-featured model with specialized attachments (oral accessory, tongs, soft brain tip) for targeted application, and the Rezzimax Tuner Mini, a compact, travel-friendly variant with built-in timers. Both are assembled and engineered in Cache Valley, Utah. The company maintains FDA registration and operates a direct-to-consumer model with a 60-day money-back guarantee. Products are marketed for both professional clinical integration and at-home personal use. Rezzimax holds FDA certification confirming product registration and quality compliance; ongoing FDA clinical studies and quality controls apply. The company emphasizes domestic manufacturing and has received recognition as part of the Coolest Thing Made in Utah 2020 initiative.

NeurOptics is a worldwide leader in pupillometry technology for critical care, neurology, neurosurgery, emergency medicine, and applied research. The company develops and markets the NPi-300 Pupillometer, a handheld device that provides objective, quantitative assessment of pupil size and reactivity independent of examiner variability. The NPi-300 is adopted in over 1,000 U.S. hospitals and represented in more than 50 countries globally. The device measures pupillary responses and constriction velocity, enabling clinicians to detect subtle changes in pupillary response that may indicate increased intracranial pressure, neurological decline, or brain injury—particularly valuable in sedated or comatose patients where subjective penlight examination is unreliable. NeurOptics also provides pupillometry instrumentation for applied research applications, supporting both human and animal research across various clinical and research settings. The company emphasizes device integration with electronic medical records (EMR) to streamline clinical workflows and enable trend analysis of pupillary data as a vital sign. The NPi-300 is used extensively in neurocritical care units, stroke services, trauma centers, and cardiac arrest care settings. Clinical evidence supports the device in management of traumatic brain injury, cardiac arrest, malignant cerebral edema, and assessment for brain death determination.

Neurodynamics Inc. is a New York–based neurosurgical device manufacturer founded in 1987, specializing in stereotactically guided catheter placement instruments for ventricular access and ventriculostomy procedures. The company's primary product is The Ghajar Guide® System, a ventricular access device that enables accurate catheter placement into the brain ventricles for cerebrospinal fluid (CSF) drainage and intracranial pressure (ICP) reduction and control. The device is designed to facilitate first-pass catheter placement and reduce complications associated with freehand ventricular catheterization. The Ghajar Guide® system is indicated for use in traumatic brain injury (TBI), hydrocephalus, and other conditions requiring emergency ventricular drainage and ICP monitoring. All products carry FDA 510(k) marketing approval. The company serves neurosurgeons and trauma centers in the United States and internationally, offering both direct sales and distribution channels. Neurodynamics manufactures and supplies specialized surgical instruments and devices for cranial neurosurgery and operates from a New York facility.

Technical Services for Electronics (TSE), operating as a brand of AMETEK Paragon Medical, is a custom medical device component manufacturer specializing in precision interconnect solutions, cable assemblies, and laser-processed components for leading medical device OEMs. The company provides collaborative engineering and advanced manufacturing capabilities across 40+ years of medical device innovation, serving electrophysiology, neuromodulation, cardiac rhythm management, patient monitoring, vascular, surgical instruments, orthopedic, and structural heart device markets. TSE manufactures components from specialty materials including Nitinol, PEEK, stainless steel, and silicone. Core offerings include custom electrical interconnects, DENSYTY interconnect systems, cable assemblies with smart PCB integration, laser ablation of polymers, fine wire components, catheter manufacturing, Nitinol laser processing, precision tube cutting, laser welding, and laser hole drilling. The company operates as part of AMETEK Inc.'s Paragon Medical division alongside brands Avicenna and Laserage. TSE provides world-class manufacturing with robust quality systems and integrative service models designed to accelerate time-to-market for innovative medical device concepts across multiple clinical specialties.

Diagnostic BioSystems Inc., founded in 1994, is a Pleasanton, California-based manufacturer of immunohistochemistry (IHC) reagents and anatomic pathology products for diagnostic and research applications. The company specializes in primary antibodies (IVD and RUO formulations for U.S. and international markets), detection systems (UnoVue™ HRP, PolyVue™ Plus HRP/DAB, Mohs™ HRP), chromogens, ancillary reagents (blockers, mounting media, buffers), and antigen retrieval solutions. DBS manufactures two proprietary automated staining instruments: the DBS HighLighter™ 360 autostainer (fully automated slide staining system) and Montage Opus365™ (antigen retrieval system). The product portfolio includes fluorescent antibodies (FITC, CF488), special stains, and accessory reagents for pathology labs. Recent product launches feature cancer-specific antibodies (CEACAM5, Uroplakin 3B, Claudin 18.2, NUT1, EGFR, CD117/c-kit, PSA). The company markets products both under IVD (in vitro diagnostic) and RUO (research use only) designations, with distribution through partnerships including Cardinal Health Scientific and ThermoFisher in the USA. DBS maintains regulatory compliance with FDA and international requirements (CE, SFDA approvals noted). The company serves anatomic pathology laboratories, cancer research institutions, and clinical diagnostic centers globally through direct sales and international distributor networks.

SOPHYSA is a French medical device manufacturer with 50 years of expertise in cerebrospinal fluid (CSF) management and neuromonitoring solutions. Headquartered in Orsay, France with manufacturing and R&D in Besançon, the company serves neurosurgery and neurocritical care specialties globally, including a US subsidiary in Crown Point, Indiana. SOPHYSA manufactures implantable and external drainage systems for hydrocephalus management, intracranial pressure (ICP) monitoring devices, and access ports for neurological applications. Core product lines include adjustable CSF shunting valves (Polaris®, Sophy® Mini SM8, Sophy® Mini SM1), anti-siphon devices (SiphonX®), external ventricular drainage systems and catheters, ICP/temperature monitoring catheters (Pressio® line), implantable access ports (Soph-A-Port®), and associated accessories and reservoirs. The Pressio® 2 system provides integrated intracranial pressure and temperature monitoring for critical care settings. All products are designed for MRI compatibility where applicable. The company serves hospitals, neurosurgical centers, and critical care facilities across multiple continents. Manufacturing capabilities include precision medical device fabrication with quality systems and regulatory compliance in multiple markets.

Electro-Cap International, Inc. is a specialized medical device manufacturer headquartered in Eaton, Ohio, founded in 1988. The company is the world leader in electrode caps for electroencephalography (EEG) and related neurological applications. Their electrode caps serve as diagnostic tools for EEG testing, neurological assessment, neurofeedback protocols, and clinical research. The product line is used across hospitals, neurosurgery departments, psychology clinics, academic universities, and private research laboratories. Electro-Cap caps are designed to enable high-quality signal acquisition for functional brain diagnostics and monitoring. The company maintains a focus on quality and integrity in manufacturing. While specific regulatory certifications and detailed product specifications are not listed on the primary web presence, the company's long operational history and established market position indicate compliance with relevant medical device standards for EEG electrode systems.

Neurotron, Incorporated is a US-based medical device manufacturer established in 1981, headquartered in Aurora, Colorado. The company specializes in the Neurometer® CPT® (Current Perception Threshold), a proprietary neurodiagnostic device for painless, non-invasive sensory nerve fiber testing. The Neurometer® CPT® evaluates small unmyelinated C-fibers, small myelinated Aδ-fibers, and large myelinated Aβ-fibers at any cutaneous site, detecting >90% of sensory nerve fiber types using a standardized, double-blind automated test procedure. FDA-cleared since 1986, the device has been used in over one million tests globally and is supported by more than 800 peer-reviewed publications. The technology quantifies both hyperesthesia and hypoesthesia, monitors nerve regeneration progression, and enables early detection of nerve damage from diabetes, carpal tunnel syndrome, spinal injury, sciatica, radiculopathy, and polyneuropathy. Unlike traditional electrodiagnostic and biopsy procedures, CPT® measurements are unaffected by skin temperature, edema, or electromagnetic interference. The device is portable, battery-powered, painless, non-invasive, and requires no special environmental shielding. Neuval® CPT® software evaluates results against established norms, manages patient records, and generates clinical reports. The company markets through direct sales and an international distributor network across China, Japan, Switzerland, Korea, Benelux, UAE, and Kuwait. Products are manufactured in the USA.

Aktina Medical Corp. is a radiation oncology equipment and services company specializing in stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), and precision localization and immobilization solutions for LINAC (linear accelerator) treatments. The company manufactures and distributes patient immobilization systems, respiratory compression devices, cone collimators for small-field radiation delivery, and quality assurance systems for radiation therapy equipment. Primary product lines include the positionPRO modular immobilization system (offering pitch and roll correction for cranial, cervical spine, and head/neck treatments), SBRT systems, Elekta small-field circular cones, respiratory compression belts, and the isoPoint machine vision platform for LINAC isocenter optimization and calibration. Aktina also provides medical physics consultation services, diagnostic and therapeutic physics support, and quality assurance solutions including the SpiroCheck Duo system for active breathing control (ABC) validation. The company serves radiation oncology departments, cancer centers, and tertiary care hospitals requiring high-precision patient positioning and LINAC calibration for intracranial, head/neck, and body-based radiation treatments. Products are designed for compatibility with Elekta LINAC platforms and emphasize both treatment precision and patient comfort through innovative immobilization technology.

BrainsWay

BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, founded in 2003 and dual-listed on NASDAQ and the Tel Aviv Stock Exchange. Headquartered in Burlington, MA, and Jerusalem, the company develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, utilizing patented H-Coil helmets for targeted brain stimulation. The Deep TMS™ system is the flagship offering, providing noninvasive treatment through electromagnetic pulses to stimulate deeper brain regions. It is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is committed to advancing neuroscience to improve mental health, emphasizing awareness and access to treatment options, particularly for those who do not respond to traditional therapies. The company also supports healthcare providers with education on the efficacy of its devices and protocols.

ARK Diagnostics Inc is a clinical laboratory diagnostics company specializing in the design, development, and manufacture of in vitro diagnostic immunoassays for therapeutic drug monitoring (TDM) and urine drug testing (UDT). The company develops next-generation homogeneous enzyme immunoassays that are liquid, stable, and ready-to-use, with applications available for automated clinical chemistry systems. ARK's product portfolio spans multiple therapeutic categories: epilepsy antiepileptic drug monitoring (gabapentin, lamotrigine, levetiracetam, topiramate, zonisamide, lacosamide, oxcarbazepine metabolite); cancer chemotherapy monitoring (methotrexate); anti-infective agents (linezolid, voriconazole); urine drug testing for substances including opioids, benzodiazepines, synthetic cannabinoids, ketamine, and ethyl glucuronide; and veterinary applications (cortisol, phenobarbital, progesterone, thyroxine, SDMA, gabapentin, levetiracetam, zonisamide). The company holds CE Mark approvals across multiple product lines and FDA clearances (510(k)) for epilepsy assays, cancer assays, and select UDT assays. Voriconazole II received FDA de novo approval. Several products are in development, including additional opioid assays, benzodiazepine formulations, antiretroviral monitoring, and oral anticoagulant assays. ARK serves clinical laboratories, hospital pathology departments, and forensic testing facilities through direct sales and international distributor networks. The company is ISO and GLP-compliant, with active participation in professional conferences (ADLM, IATDMCT, CAT).

Ives EEG Solutions, Inc. manufactures and supplies EEG electrodes and electrode harness systems for clinical, research, and veterinary applications. Founded in 1995, the company specializes in disposable conductive plastic electrodes (DCPE), electrode harnesses, subdermal wire electrodes, and MR/CT-compatible electrode kits. Products are designed for intensive care units (ICUs), epilepsy monitoring units (EMUs), and long-term EEG monitoring. The company emphasizes skin-safe, child-friendly electrode designs to minimize skin breakdown in neonates and sensitive-skin patients. All products are manufactured to support EEG accuracy and cost-effectiveness for hospitals and clinical centers. The company serves hospitals, clinics, research institutions, and veterinary centers globally. Ives EEG Solutions is preferred by EEG technologists for product quality, ease of use, and customer service. The firm also offers free product samples and expert consultation services to support customer needs.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.

NeuraSignal is a medical technology company specializing in advanced transcranial Doppler (TCD) ultrasound systems enhanced through robotics, artificial intelligence, and cloud computing. Founded in 2013 and based in Los Angeles, the company develops FDA-cleared intelligent ultrasound platforms designed to automate and improve cerebral hemodynamics assessment for stroke detection, patent foramen ovale (PFO) screening, and vasospasm monitoring. The NG2 Intelligent Ultrasound system uses robotic control and machine learning algorithms to automatically locate the temporal window and lock onto cerebral blood flow signals with accuracy comparable to expert sonographers, while eliminating operator variability. The NeuraSignal Platform provides cloud connectivity enabling remote access, real-time data collaboration, and advanced analytics for clinical decision-making. Their portable Lucid™ TCD systems support both clinical deployment in hospital settings and international research initiatives. The technology is particularly valued in comprehensive stroke centers and neuroscience programs for its noninvasive nature, painless administration, and superior detection rates—clinical data demonstrates 3× shunt detection rates and 2.7× detection of intervenable shunts compared to standard transthoracic echocardiography (TTE).

Neuromod Devices Limited is a global medical technology company specializing in tinnitus treatment through neuromodulation. The company developed and commercialized Lenire, the first and only FDA-approved bimodal neuromodulation device for tinnitus treatment. Lenire combines sound stimulation with electrical stimulation to target tinnitus through coordinated neural pathways and has demonstrated safety and efficacy across three large-scale independent clinical trials involving over 600 patients, with results published in peer-reviewed scientific journals. Neuromod holds 136+ neuromodulation patents for tinnitus treatment across 37 countries. The company operates a global distribution network with over 200 clinicians providing Lenire services across Europe and the United States, supported by more than 130 clinics. Neuromod maintains ISO 13485 quality standards and adheres to rigorous regulatory requirements. The company provides comprehensive practice enablement services including clinical training, commercial support, and an integrated Partner Platform that handles clinic onboarding, scalable operations, and patient care coordination. Manufacturing is industrialized with full supply chain redundancy. Neuromod serves ENT specialists, audiologists, and hearing care practitioners treating chronic tinnitus patients seeking FDA-cleared therapeutic alternatives.

Turing Medical is a precision brain mapping and neuromodulation therapy company. The company develops PACE (Personalized Adaptive Cortical Electro-Stimulation), a precision-guided neuromodulation therapy platform designed to treat severe depression and chronic pain through adaptive cortical stimulation. PACE combines precision functional mapping with cortical stimulation, intended to restore healthy brain activity without the invasiveness of deep brain surgery—analogous to how a pacemaker restores cardiac rhythm. The company was formerly known as Nous Imaging and is led by co-founders Nico Dosenbach, M.D., PhD and Damien Fair, PA-C, PhD, both neuroscience researchers with published work in Nature on brain plasticity and precision functional mapping. Turing Medical's research focuses on reproducible brain-wide association studies, precision dynamical mapping, and mind-body network discovery. The company has appointed Kevin King, a medtech executive with three decades of experience in precision medicine and diagnostic technologies, as President and CEO as of April 2025, signaling expansion into clinical applications and commercialization. Turing Medical serves the neurology, psychiatry, and pain management markets. The company's technology platform leverages advanced functional brain imaging and mapping capabilities to enable personalized treatment targeting.